1:10 PM
Dec 30, 2016
 |  BC Week In Review  |  Clinical News  |  Regulatory

Anagrelide CR regulatory update

Galena said FDA confirmed that a Phase III trial comparing anagrelide CR vs. best available therapy in patients with essential thrombocythemia would be appropriate for an NDA submission...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >